Targeting Colon Cancers with Mutated BRAF and Microsatellite Instability

Area of Science:

• Oncology
• Genetics
• Immunology

Background:

• Colon cancer (CRC) with BRAF mutations and microsatellite instability (MSI) affects ~10% of patients.
• This subtype originates from serrated polyps and exhibits a high genomic mutation rate.
• The BRAF V600E mutation activates the MAPK pathway, but BRAF inhibitors have shown limited efficacy in metastatic CRC due to pathway reactivation.

Purpose of the Study:

• To review therapeutic opportunities for BRAF-mutated, MSI-high colon cancer.
• To highlight recent advancements in combination therapy for MAPK pathway inhibition.
• To discuss the potential of immune checkpoint therapy for this CRC subtype.

Main Methods:

• Literature review focusing on BRAF mutation, MSI phenotype, and therapeutic strategies in colon cancer.
• Analysis of current research on MAPK pathway inhibition and combination therapies.
• Evaluation of emerging immune checkpoint therapies and their relevance to MSI-high tumors.

Main Results:

• BRAF inhibitors alone have limited clinical benefit in metastatic CRC due to MAPK reactivation.
• New combination therapy approaches are being developed to overcome adaptive resistance.
• The MSI phenotype leads to neo-antigen generation and high tumor-infiltrating lymphocytes, suggesting sensitivity to immunotherapy.

Conclusions:

• BRAF-mutated, MSI-high colon cancer presents unique therapeutic challenges and opportunities.
• Combination therapies targeting the MAPK pathway are crucial for improving treatment outcomes.
• Immune checkpoint therapy holds significant promise for this patient subgroup due to its immunogenic nature.